Revvity, Inc. (RVTY), a health science solutions company, on Tuesday reported higher net income in the first quarter compared with the previous year.
For the first quarter, income from operations increased to $40.89 million from $41.67 million in the previous year.
Earnings per share were $0.37 versus 0.35 last year.
On a pro forma basis, earnings per share were 0.40 versus loss per share of $0.13 last year.
Adjusted earnings per share were $1.06 versus 1.01 last year.
On a pro forma basis, adjusted earnings per share were $1.04 versus $0.95 last year.
Operating income rose to $75.89 million from $72.23 million in the same period a year ago.
On a pro forma basis, operating income surged to $80.08 million from $20 million in the prior year.
Revenue increased to $711.12 million from $664.76 million in the previous year.
On a pro forma basis, revenue also jumped to $686.91 million from $628.70 million in the prior year.
Looking ahead, the company forecasts pro forma revenue of $2.81to $2.84 billion and pro forma adjusted earnings per share of $5.20 to $5.30.
Further, the company plans to divest its China Immunodiagnostics business, which accounted for about 6% of fiscal 2025 revenue, with a deal expected to be signed in the second quarter of 2026 and completed in 2027.
In the pre-market, Revvity is 3.01% higher at $89.11 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.